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Edited by Laszlo NagyAbstract Adiponectin exerts an insulin-sensitizing eﬀect,
improving insulin action in peripheral tissues and restraining
insulin resistance. Here, we explore the hypothesis that adipo-
nectin can reproduce some of the actions of insulin/leptin in the
hypothalamus. The presence of AdipoR1 and AdipoR2 was
mapped to the arcuate and lateral hypothalamic nuclei. Icv
adiponectin reduced food intake, which was accompanied by acti-
vation/engagement of IRS1/2, ERK, Akt, FOXO1, JAK2 and
STAT3. All these actions were dependent on AdipoR1, since
inhibition of this receptor, and not of AdipoR2, completely re-
versed the eﬀects described above. Thus, adiponectin acts in
the hypothalamus, activating elements of the canonical insulin
and leptin signaling pathways and promoting reduction of food
intake.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The collagen-like protein adiponectin is the most abundant
secretory protein produced by the adipose tissue [1]. It circu-
lates in lg concentrations and acts though at least two atypical
receptors, AdipoR1 and AdipoR2, to exert important func-
tions in the control of glucose and lipid metabolism [2–4].
In peripheral tissues, adiponectin can sensitize and repro-
duce a number of insulin actions [2,5]. In animal models of
obesity and diabetes, treatment with adiponectin reduces
blood glucose levels by hampering hepatic glucose production
and increasing muscle glucose uptake. In addition, adiponectin
increases free fatty acid oxidation in liver and muscle, which
contributes to reduce the levels of free fatty acids in plasma
[6–9]. Although many of the eﬀects of adiponectin depend on
AMPK activation [8], several studies have shown that upon di-
rect adiponectin stimulus the activation of elements of the
canonical insulin signaling pathway is achieved [10,11].
In the hypothalamus, insulin acts in concert with leptin to
provide the most robust adipostatic stimulus, informing the
central nervous system about the peripheral energy stores*Corresponding author. Present address: Departamento de Clı´nica
Me´dica – Faculdade de Cieˆncias Me´dicas, Universidade Estadual de
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doi:10.1016/j.febslet.2008.03.037and coordinating a complex neuron circuitry that maintains
body energy homeostasis [12]. Most of the actions of insulin
and leptin in hypothalamus are delivered by cognate recep-
tor-mediated activation of IRS1/2–PI3 kinase–Akt–FOXO1
and JAK2–STAT3 signaling pathways, which control neuro-
transmitter gene expression and neuronal ﬁring [13,14]. Recent
studies have suggested that a phenomenon of hypothalamic
resistance to insulin and leptin may play a role in the develop-
ment of obesity [15–17]. Therefore, deﬁning strategies to boost
insulin and leptin actions in the hypothalamus may have ther-
apeutic implications for this disease.
Here, we have evaluated the eﬀects of ivc injected adiponec-
tin in the control of food intake and on the activation of sig-
naling pathways involved in insulin and leptin actions in the
hypothalamus. Our results show that adiponectin provides a
discrete anorexigenic stimulus and activates signal transduc-
tion through the IRS1/2–Akt–FOXO1 and JAK2–STAT3
pathways.2. Materials and methods
2.1. Antibodies, chemicals and buﬀers
The reagents for SDS–polyacrylamide gel electrophoresis and immu-
noblotting were from Bio-Rad (Richmond, CA, USA). HEPES, phen-
ylmethylsulfonyl ﬂuoride (PMSF), aprotinin, dithiothreitol, Triton
X-100, Tween 20, glycerol and bovine serum albumin (fraction V) were
from Sigma (St. Louis, MO, USA). Nitrocellulose membrane (BA85,
0.2 lm) was from Amersham (Aylesbury, UK). Amobarbital and hu-
man recombinant insulin (Humulin R) were from Lilly (Indianapolis,
IN, USA). Recombinant leptin was from Calbiochem (La Jolla, CA,
USA). Rat recombinant adiponectin was from BioVision Research
Products (Mountain View, CA, USA). Anti-insulin receptor substrate
1 (IRS1) (sc-560, rabbit polyclonal), anti-insulin receptor substrate 2
(IRS2) (sc-8299, rabbit polyclonal), anti-JAK2 (sc-278, rabbit poly-
clonal), anti-Akt (sc-1618, goat polyclonal), anti-phosphotyrosine
(pY) (sc-508, mouse monoclonal), anti-phospho [Ser473] Akt (sc-
7985-R, rabbit polyclonal), anti-STAT3 (sc-7179, rabbit polyclonal),
anti-phospho [Tyr705] STAT3, anti-FOXO1 (sc-11350, rabbit poly-
clonal), anti-phospho [Ser256] FOXO1 (sc-22158-R, rabbit polyclonal),
anti-AdipoR1 (sc-46748, goat polyclonal), and anti-AdipoR2
(sc-46755, goat polyclonal) antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Anti-neuronal N antigen (NeuN) anti-
body (MAB 377, mouse monoclonal) was from Chemicon-Millipore
(Billerica, MA, USA).
2.2. Animal model and experimental protocols
In all experiments 8 weeks old, male Wistar rats with a body mass of
250–300 g were employed. The animals were maintained on a 12:12 h
artiﬁcial light-dark cycle and housed in individual cages. The investiga-
tion followed the University guidelines for the use of animals in exper-
imental studies and conforms to the Guide for the Care and Use ofblished by Elsevier B.V. All rights reserved.
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Health (NIH publication No. 85-23 revised 1996). For histology and
for determination of AdipoR1 and AdipoR2 expression by immuno-
blot, non-icv cannulated rats were employed. For the remainder of
the experiments the animals were stereotaxically instrumented to re-
ceive a cannula placed in the lateral ventricle, as previously described
[18]. After seven days, the correct location of the cannula was tested
by injecting 2.0 ll angiotensin II (106 M) and determining the thirst
response [14]. For that, rats were water deprived for 2 h and immedi-
ately after icv injection of angiotensin II a bottle containing 10.0 ml
water was made available. Only the rats spontaneously drinking at
least 5.0 ml water in 30 min were considered correctly cannulated
and used in the experiments. For evaluation of spontaneous food
intake the rats were food deprived for 6 h (12:00–6:00 PM) and then
treated with a single dose (2.0 ll) of insulin (106 M), leptin
(106 M), or adiponectin (105–1011 M, corresponding to 0.6 lg to
0.6 pg). For immunoblot and immunoprecipitation experiments, icv
cannulated rats were acutely treated with a single dose (2.0 ll) of
insulin (106 M), leptin (106 M), or adiponectin (107 M, correspond-
ing to 6.0 ng) and the hypothalami were obtained for protein extract
preparation. In some experiments, the rats were pre-treated for 1–3
days with two daily doses (2.0 nmol) of antisense oligonucleotides
against AdipoR1 (ASOR1), AdipoR2 (ASOR2) or a scrambled control
(Scr).
2.3. Antisense oligonucleotides
AdipoR1 and AdipoR2 phosphorothioate modiﬁed antisense oligo-
nucleotides were designed based on the Rattus norvegicus mRNA se-
quences deposited at the NIH-PubMed database and were submitted
to BLAST analysis to assure speciﬁcity. The elected sequences were
5 0-CGGGATAGGAGTGGGT-3 0 (AdipoR1, ASOR1) and 5 0-
TCGGTGTTCGGTTGG-30 (AdipoR2, ASOR2). Synthesis was per-
formed by Invitrogen (Carlsbad, CA, USA).
2.4. Hypothalamus histology
Hydrated, 5.0 lm sections of frozen hypothalamus specimens were
obtained from ﬁve distinct rats. The distributions of AdipoR1 and
AdipoR2 were evaluated by indirect immunoﬂuorescence, staining in
parallel with the labeling of neurons with NeuN, as previously de-
scribed [19]. Rats were killed by deep anesthesia and submitted to
whole body perfusion initially with saline, followed by 4% paraformal-
dehyde in 0.1% phosphate buﬀer (pH 7.4). The brains were removed
and kept in 4% paraformaldehyde for 24 h prior to being transferred
to the cryoprotective 20% sucrose/0.1% phosphate buﬀer (pH 7.4)
for 36 h, and then to liquid nitrogen freezing. Coronal sections were
obtained at bregma 2.6 mm [18]. Initially, the sections were incu-
bated for 30 min with 2% (v/v) normal goat serum and subsequently
incubated for 12 h in a moister chamber at 4 C with the primary anti-
bodies against AdipoR1 or Adipo R2 (1:50, 1:100 and 1:200 dilutions).
In some sections a second primary antibody against NeuN (1:200 dilu-
tion) was used in similar incubation protocol. FITC (1:500) and/or
TRITC (1:200) conjugated secondary antibodies were used in 2 h (dark
moister chamber) incubations. Controls lacking the incubations with
primary antibodies were run in parallel. Sections were mounted with
DAPI (diamidino phenylindole, Calbiochem, La Jolla, CA, USA) for
nuclear counterstaining.
2.5. Immunoprecipitation and immunoblotting
For evaluation of protein expression and activation of signal trans-
duction pathways, the hypothalami of anesthetized rats were excised
and immediately homogenized in solubilization buﬀer at 4 C [1% Tri-
ton X-100, 100 mM Tris–HCl (pH 7.4), 100 mM sodium pyrophos-
phate, 100 mM sodium ﬂuoride, 10 mM EDTA, 10 mM sodium
orthovanadate, 2.0 mM PMSF and 0.1 mg aprotinin/ml] with a Poly-
tron PTA 20S generator (model PT 10/35; Brinkmann Instruments,
Westbury, NY, USA). Insoluble material was removed by centrifuga-
tion for 40 min at 11,000 rpm in a 70.Ti rotor (Beckman) at 4 C. The
protein concentration of the supernatants was determined by the Brad-
ford dye method. Aliquots of the resulting supernatants containing
2.0 mg of total protein were used for immunoprecipitation with speciﬁc
antibodies at 4 C overnight, followed by SDS/PAGE, transfer to
nitrocellulose membranes and blotting. The dilutions of the antibodies
used in immunoprecipitations were 1:200 for IRS1 and IRS2 and 1:100
for JAK2. In direct immunoblot experiments, 0.2 mg of protein ex-tracts were separated by SDS–PAGE, transferred to nitrocellulose
membranes and blotted with antibodies. The dilutions of the antibod-
ies used in immunoblots were 1:2000 for phosphotyrosine, ERK and
phospho-FOXO1 and 1:1000 for phospho-Akt and phospho-STAT3.
Speciﬁc bands were detected by chemiluminescence and visualization
was performed by exposure of the membranes to RX-ﬁlms.
2.6. Protocol for testing the speciﬁcity of the AdipoR1 and AdipoR2
antibodies
Prior to starting the immunohistochemistry and immunoprecipita-
tion/immunoblotting experiments the speciﬁcities of the AdipoR1
and AdipoR2 antibodies were tested. For that, total protein extracts
(0.2 mg) obtained from hypothalamus were submitted to ﬁve rounds
of consecutive immunoprecipitations with either antibody. The immu-
noprecipitates obtained in each round were separated by SDS/PAGE,
transferred to nitrocellulose membranes and blotted with anti-Adi-
poR1 or AdipoR2 antibodies, respectively, or with anti-IRS1 anti-
body. Typically, for AdipoR1 and AdipoR2, an antibody-speciﬁc
complete immunodepletion was obtained after 3–4 rounds of consecu-
tive immunoprecipitations. No depletion of IRS1 was observed in
either condition.
2.7. ELISA for determination of APPL1 binding to AdipoR1 and
AdipoR2
A recombinant peptide spanning the PTB domain of APPL1 (adap-
tor protein containing pleckstrin homology domain 1) (residues 497–
636) was bound to ELISA plates and used as a target for AdipoR1
and AdipoR2 obtained from hypothalamic protein extracts of icv
adiponectin (2.0 ll, 107 M) treated rats. Control rats were icv injected
with saline and some rats were pre-treated with ASOR1 or ASOR2.
Binding was determined by speciﬁc AdipoR1 and AdipoR2 antibodies
interacting with the trapped receptors and development was obtained
by anti-goat Fc peroxidase conjugated secondary antibodies.
2.8. Statistical analysis
Speciﬁc protein bands present in the blots were quantiﬁed by digital
densitometry (ScionCorp, Inc. Frederick, MD, USA). Mean val-
ues ± S.E.M. obtained from densitometry scans, food intake measure-
ments and ELISA were compared utilizing Turkey–Kramer test
(ANOVA) or Students t-test, as appropriate; P < 0.05 was accepted
as statistically signiﬁcant.3. Results
3.1. Adiponectin reduces spontaneous food intake
When this study was ﬁrst designed, no previous evaluation
of the eﬀects of icv injected adiponectin on food intake was
available. Therefore, icv cannulated rats were acutely treated
with adiponectin (2.0 ll, 105–1011 M) and spontaneous food
intake was determined over 12 h. As shown in Fig. 1A, adipo-
nectin promoted an up to 40% reduction in food intake, with
the greatest inhibition occurring with 105 and 107 M. This
was signiﬁcantly diﬀerent from the control, but the eﬀect was
milder than those produced by insulin or leptin. In the ﬁrst
set of experiments, the number of experimental animals was
ﬁve per group. However, during preparation of this manu-
script, a paper by Kubota and colleagues [20] reported that
adiponectin produced an orexygenic, rather than an anorexy-
genic eﬀect. Thus, we decided to increase the number of obser-
vations to 15. The new set of experiments containing ten
additional observations with adiponectin 107 M is depicted
in Fig. 1B, and conﬁrms our initial ﬁndings.
3.2. AdipoR1 and AdipoR2 are expressed predominantly in
neurons of the arcuate and lateral hypothalamic nuclei
To evaluate the presence and distribution of the receptors
for adiponectin in the hypothalamus, we initially prepared a
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Fig. 1. Icv cannulated rats were treated with a single dose (2.0 ll) of saline (CT), insulin (In), leptin (Lep), or adiponectin in concentrations ranging
from 105–1011 M (Ad5-Ad11), and food intake (g) was determined over the next 12 h (A). An extended number of rats were evaluated for 12 h-
food intake after icv saline (CT) or adiponectin (Ad7) treatment (B). Hypothalamic protein extracts were separated by SDS–PAGE, transferred to
nitrocellulose membranes and blotted with antibodies against AdipoR1, AdipoR2, leptin receptor (ObR) and insulin receptor (IR) (C). Five lm
sections at bregma 2.6 mm, obtained from hypothalami of rats were used in immunohistochemistry experiments to determine the expressions of
AdipoR1 and AdipoR2 in the arcuate (Arc) and lateral hypothalamic (LH) nuclei (D). In some experiments, double immunoﬂuorescence stanning
was performed with NeuN and AdipoR1 or AdipoR2 antibodies, the bottom microphotographs depict neurons from the arcuate nucleus exhibiting
peripheral labeling for the receptors (AdipoR1 or AdipoR2) (FITC) and nuclear labeling for NeuN (TRITC) (D). Icv cannulated rats were treated
twice-a-day for three days with saline (CT), scrambled (Scr) oligonucleotide, anti-AdipoR1 (ASOR1) or anti-AdipoR2 (ASOR2) antisense
oligonucleotides. At the end of the experimental period, protein extracts obtained from the hypothalami were separated by SDS–PAGE, transferred
to nitrocellulose membranes and blotted (IB) with anti-AdipoR1 or anti-AdipoR2 antibodies (E). In A, C–E, n = 5, in B, n = 10; *P < 0.05 vs. CT, in
A, B and E; §P < 0.05 vs. In, in A.
A. Coope et al. / FEBS Letters 582 (2008) 1471–1476 1473total protein extract from hypothalamus and used AdipoR1
and AdipoR2 speciﬁc antibodies in immunoblot assays. As
shown in Fig. 1C, both receptors are detected at the expected
molecular weight, as are the insulin and leptin receptors. Fur-
thermore, in immunoﬂuorescence staining the adiponectin
receptors were localized preferentially in neurons of the arcu-
ate and lateral hypothalamic nuclei (Fig. 1D). In addition,some cells of the paraventricular nucleus also expressed both
the receptors (not shown).
3.3. The hypothalamic expressions of AdipoR1 and AdipoR2 are
inhibited by speciﬁc antisense oligonucleotides
To further evaluate the expressions of the adiponectin recep-
tors in the hypothalamus, species-speciﬁc phosphorothioate
1474 A. Coope et al. / FEBS Letters 582 (2008) 1471–1476modiﬁed antisense oligonucleotides were designed and tested
in time-course experiments. As shown in Fig. 1E, three days
injection protocols of two daily doses of either antisense oligo-
nucleotide were both capable of reducing the expressions of
AdipoR1 and AdipoR2 by 65% (P < 0.05) and 80%
(P < 0.05), respectively.
3.4. Adiponectin induces the associations of AdipoR1 and
AdipoR2 with APPL1 in the hypothalamus
APPL1 is an adaptor protein rapidly engaged following
adiponectin ligation to both its receptors [21]. To evaluate
the molecular activation of the adiponectin receptors expressed
in hypothalamus, icv cannulated rats were treated with a single
icv dose of adiponectin (2.0 ll, 107 M) and the hypothalami
were obtained for protein extract preparations. As shown in
Fig. 2A and B, both AdipoR1 and AdipoR2 from adiponec-
tin-treated samples associated with the adaptor protein
APPL1. The inhibition of either AdipoR1 or AdipoR2 expres-
sions with speciﬁc antisense oligonucleotides promoted a
receptor type-speciﬁc inhibition of the association with
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Fig. 2. Icv cannulated rats were treated twice-a-day, for three days,
with saline (CT and Ad) or antisense oligonucleotides against
AdipoR1 (ASOR1) or AdipoR2 (ASOR2). On the fourth day, the
rats received a single dose (2.0 ll) of saline (CT) or adiponectin
(107 M) (Ad, ASOR1 and ASOR2) and, after 10 min, the hypotha-
lami were obtained and a protein extract prepared to be used in an
ELISA assay for determination of AdipoR1 (A) or AdipoR2 (B)
binding to APPL1. In all experiments n = 5, *P < 0.05 vs. CT;
§P < 0.05 vs. Ad. BG, background binding.3.5. Adiponectin activates signal transduction through elements
of the canonical insulin and leptin signaling pathways
To evaluate whether icv injected adiponectin can activate
proteins involved in classical insulin and leptin signal transduc-
tion, icv cannulated rats were treated with a single icv dose of
insulin, leptin or adiponectin and hypothalami were obtained
for immunoprecipitation and immunoblot studies. As shown
in Fig. 3A, adiponectin induced the tyrosine phosphorylations
of IRS1 [peak at 10 min, increased 8.4 (±1.8)-fold, P < 0.05 vs.
time 0], IRS2 [peak at 10 min, increased 2.8 (±0.3)-fold,
P < 0.05 vs. time 0] and ERK [peak at 10 min, increased 4.5
(±0.7)-fold, P < 0.05 vs. time 0], and the serine phosphoryla-
tions of Akt [peak at 10 min, increased 3.4 (±0.5)-fold,
P < 0.05 vs. time 0] and FOXO1 [peak at 20 min, increased
5.1 (±1.0)-fold, P < 0.05 vs. time 0]. In addition, signal trans-
duction through JAK2 [tyrosine phosphorylation, peak at
10 min, increased 3.2 (±0.8)-fold, P < 0.05 vs. time 0] and
STAT3 [tyrosine phosphorylation, peak at 20 min, increased
3.9 (±0.7)-fold, P < 0.05 vs. time 0] were also activated in re-
sponse to adiponectin (Fig. 3B).
3.6. AdipoR1 mediates the anorexigenic and molecular actions of
adiponectin through IRS1/2–Akt–FOXO1 and JAK2–
STAT3 signaling pathways in the hypothalamus
To determine the eﬀect of each of the adiponectin receptors
on the anorexigenic and molecular actions of this adipokine in
the hypothalamus, rats were icv treated with the speciﬁc anti-
sense oligonucleotides and then used in experiments to evalu-
ate food intake and signal transduction. As depicted in
Fig. 4A, only the inhibition of AdipoR1 expression, and not
of AdipoR2, was capable of reversing the anorexygenic eﬀects
of adiponectin. In addition, the inhibition of AdipoR1 com-
pletely reversed the adiponectin-induced activation of signal
transduction through IRS1/2–Akt–FOXO1 (Fig. 4B) and
through JAK2–STAT3 (Fig. 4C).4. Discussion
The main objective of this study was to test the hypothesis
that adiponectin can exert some insulin- and leptin-like actions
in the hypothalamus. It is well known that, in peripheral tis-
sues, adiponectin possesses an insulin-sensitizing eﬀect that im-
proves muscle glucose uptake and reduces liver
gluconeogenesis [2]. Until the beginning of the execution of
this work, no study exploring the actions of this adipokine in
the hypothalamus was available.
Since the most remarkable eﬀect of both insulin and leptin,
in the hypothalamus, is to reduce spontaneous food intake,
we begun by testing the capacity of adiponectin to reproduce
this phenomenon. We observed that adiponectin reduced food
intake in a dose-dependent fashion by approximately 40%.
This eﬀect was milder than those produced by insulin and lep-
tin. During preparation of this manuscript, a study by Kubota
and colleagues [20] showed that adiponectin stimulated, rather
than inhibited, food intake. To assure that our data was cor-
rectly collected we evaluated ten more rats, using the dose of
107 M adiponectin, which provided a reproducible inhibition
of food intake, as seen in the ﬁrst set of experiments. Checking
for the details of the protocols employed by Kubota and col-
leagues [2,20] that could explain the opposite results, we found
two major diﬀerences. Firstly, in their study, adiponectin was
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samples were obtained according to the time course, as depicted (0–20 min). Protein extracts were employed in immunoprecipitation (IP) assays to
purify IRS1, IRS2 (A) and JAK2 (B). Immunoprecipitates or total extracts were separated by SDS–PAGE, transferred to nitrocellulose membranes
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than directly in the hypothalamus. Secondly, in their protocol,
fed instead of fasting mice were compared. Both these diﬀer-
ences may have profound implications in the ﬁnal results. With
regard to the peripheral injection of the adipokine, at least two
recent studies have shown that adiponectin cannot promptly
cross the blood-brain barrier [22,23]. As adiponectin transits
in the blood predominantly as hexameric and multimeric com-
plexes [2,21], it is expected that a speciﬁc transport system ex-
ists to provide its access to the central nervous system.
Depending on the rate of this transport, the eﬀects observed
by Kubota after only 6 h injection, could be due to indirectmechanisms. Regarding the protocol for determination of food
intake, most of the data analyzing leptin and insulin action in
the hypothalamus, published so far, used fasting animals [13–
15,22]. These protocols provide a reproducible tool for stud-
ding the eﬀect of peripheral hormones on the control of food
intake. The evaluation of food intake in fed animals, must take
into account the inﬂuence of the postprandial levels of gut-
derived hormones and also of insulin and leptin [12,16,23].
Next, we evaluated the expression and distribution of the
two known adiponectin receptors in the hypothalamus. First,
using immunoblot, we showed that both receptors are pres-
ent in this anatomical site. Immunohistochemistry then
1476 A. Coope et al. / FEBS Letters 582 (2008) 1471–1476demonstrated their predominant distribution in the arcuate
and lateral hypothalamic nuclei. Some expression was also
seen in the paraventricular nucleus. These results are in perfect
agreement with previous studies [20].
AdipoR1 and AdipoR2 are atypical receptors and, appar-
ently, the main interface utilized to deliver their signals into
the cells is the adaptor protein, APPL1 [24]. As in peripheral
tissues and in isolated cell systems [2,5,7], we showed here that,
in the hypothalamus, both AdipoR1 and AdipoR2 can inter-
act, in an adiponectin-stimulated-dependent fashion, with
APPL1, suggesting that the signaling system for adiponectin
is preserved in this organ.
In the next set of experiments, we showed that adiponectin
can induce the molecular activation of proteins that belong
to the canonical insulin and leptin signaling pathways. The
pattern of activation followed a time-course similar to those
induced by insulin and leptin [13–15,22], and the dose of
adiponectin employed provided a local concentration within
the physiological range [20], suggesting that this is indeed a
physiological phenomenon. In peripheral tissues, similar re-
sults concerning the activation of the insulin signaling pathway
was observed [10]. However, to our knowledge, this is the ﬁrst
report of the activation of JAK2-STAT3 signaling by adipo-
nectin.
Finally, by using a pair of AdipoR1 and AdipoR2 speciﬁc
antisense oligonucleotides, we evaluated the role of each recep-
tor in the hypothalamic actions of adiponectin. Only the inhi-
bition of AdipoR1 was capable of reversing the actions of
adiponectin on the control of food intake and on the activation
of the signal transduction through IRS1/2–Akt–FOXO1 and
JAK2–STAT3.
In conclusion, this study shows that adiponectin, acting
through the AdipoR1 receptor, can inhibit food intake and
activate signal transduction through the IRS1/2–Akt–FOXO1
and JAK2–STAT3 pathways in the hypothalamus of rats.
Based on another study [20], we suspect that this is a time-
and dose-dependent eﬀect, which may suﬀer variations
depending on the route of administration, dose and timing.
Further studies will be required to fully characterize the phys-
iological and pharmacological actions of adiponectin in the
hypothalamus.
Acknowledgements: This work was supported by Fundac¸a˜o de Amparo
a` Pesquisa do Estado de Sa˜o Paulo (FAPESP) and Conselho Nacional
de Pesquisa (CNPq). We are indebted to Dr. N. Conran for English
editing and to G. Ferraz for technical assistance.References
[1] Yildiz, B.O., Suchard, M.A., Wong, M.L., McCann, S.M. and
Licinio, J. (2004) Alterations in the dynamics of circulating
ghrelin, adiponectin, and leptin in human obesity. Proc. Natl.
Acad. Sci. USA 101, 10434–10439.
[2] Kadowaki, T. and Yamauchi, T. (2005) Adiponectin and adipo-
nectin receptors. Endocr. Rev. 26, 439–451.
[3] Yamauchi, T. et al. (2003) Cloning of adiponectin receptors that
mediate antidiabetic metabolic eﬀects. Nature 423, 762–769.
[4] Arita, Y. et al. (1999) Paradoxical decrease of an adipose-speciﬁc
protein, adiponectin, in obesity. Biochem. Biophys. Res. Com-
mun. 257, 79–83.[5] Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K. and
Tobe, K. (2006) Adiponectin and adiponectin receptors in insulin
resistance, diabetes, and the metabolic syndrome. J. Clin. Invest.
116, 1784–1792.
[6] Karbowska, J. and Kochan, Z. (2006) Role of adiponectin in the
regulation of carbohydrate and lipid metabolism. J. Physiol.
Pharmacol. 57 (Suppl. 6), 103–113.
[7] Berg, A.H., Combs, T.P., Du, X., Brownlee, M. and Scherer, P.E.
(2001) The adipocyte-secreted protein Acrp30 enhances hepatic
insulin action. Nat. Med. 7, 947–953.
[8] Yamauchi, T. et al. (2002) Adiponectin stimulates glucose
utilization and fatty-acid oxidation by activating AMP-activated
protein kinase. Nat. Med. 8, 1288–1295.
[9] Yoon, M.J., Lee, G.Y., Chung, J.J., Ahn, Y.H., Hong, S.H. and
Kim, J.B. (2006) Adiponectin increases fatty acid oxidation in
skeletal muscle cells by sequential activation of AMP-activated
protein kinase, p38 mitogen-activated protein kinase, and perox-
isome proliferator-activated receptor alpha. Diabetes 55, 2562–
2570.
[10] Wang, C., Mao, X., Wang, L., Liu, M., Wetzel, M.D., Guan,
K.L., Dong, L.Q. and Liu, F. (2007) Adiponectin sensitizes
insulin signaling by reducing p70 S6 kinase-mediated serine
phosphorylation of IRS-1. J. Biol. Chem. 282, 7991–7996.
[11] Sevillano, J., de Castro, J., Bocos, C., Herrera, E. and Ramos,
M.P. (2007) Role of insulin receptor substrate-1 serine 307
phosphorylation and adiponectin in adipose tissue insulin resis-
tance in late pregnancy. Endocrinology 148, 5933–5942.
[12] Schwartz, M.W., Woods, S.C., Porte Jr., D., Seeley, R.J. and
Baskin, D.G. (2000) Central nervous system control of food
intake. Nature 404, 661–671.
[13] Xu, A.W., Kaelin, C.B., Takeda, K., Akira, S., Schwartz, M.W.
and Barsh, G.S. (2005) PI3K integrates the action of insulin and
leptin on hypothalamic neurons. J. Clin. Invest. 115, 951–958.
[14] Carvalheira, J.B. et al. (2001) Insulin modulates leptin-induced
STAT3 activation in rat hypothalamus. FEBS Lett. 500, 119–124.
[15] De Souza, C.T., Araujo, E.P., Bordin, S., Ashimine, R., Zollner,
R.L., Boschero, A.C., Saad, M.J. and Velloso, L.A. (2005)
Consumption of a fat-rich diet activates a proinﬂammatory
response and induces insulin resistance in the hypothalamus.
Endocrinology 146, 4192–4199.
[16] Flier, J.S. (2004) Obesity wars: molecular progress confronts an
expanding epidemic. Cell 116, 337–350.
[17] Munzberg, H. and Myers Jr., M.G. (2005) Molecular and
anatomical determinants of central leptin resistance. Nat. Neu-
rosci. 8, 566–570.
[18] Paxinos, G., Watson, C.R. and Emson, P.C. (1980) AChE-stained
horizontal sections of the rat brain in stereotaxic coordinates. J.
Neurosci. Meth. 3, 129–149.
[19] Bertelli, D.F. et al. (2006) Phosphoinositide-speciﬁc inositol
polyphosphate 5-phosphatase IV inhibits inositide trisphosphate
accumulation in hypothalamus and regulates food intake and
body weight. Endocrinology 147, 5385–5399.
[20] Kubota, N. et al. (2007) Adiponectin stimulates AMP-activated
protein kinase in the hypothalamus and increases food intake.
Cell Metab. 6, 55–68.
[21] Tsao, T.S., Tomas, E., Murrey, H.E., Hug, C., Lee, D.H.,
Ruderman, N.B., Heuser, J.E. and Lodish, H.F. (2003) Role of
disulﬁde bonds in Acrp30/adiponectin structure and signaling
speciﬁcity. Diﬀerent oligomers activate diﬀerent signal transduc-
tion pathways. J. Biol. Chem. 278, 50810–50817.
[22] Torsoni, M.A., Carvalheira, J.B., Pereira-Da-Silva, M., de
Carvalho-Filho, M.A., Saad, M.J. and Velloso, L.A. (2003)
Molecular and functional resistance to insulin in hypothalamus of
rats exposed to cold. Am. J. Physiol. Endocrinol. Metab. 285,
E216–E223.
[23] Murphy, K.G. and Bloom, S.R. (2006) Gut hormones and the
regulation of energy homeostasis. Nature 444, 854–859.
[24] Mao, X. et al. (2006) APPL1 binds to adiponectin receptors and
mediates adiponectin signalling and function. Nat. Cell Biol. 8,
516–523.
